AI assistant
BIOGEN INC. — Director's Dealing 2023
Feb 14, 2023
30291_dirs_2023-02-14_f9074e46-04a4-4d63-b7bf-844913870ae0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2023-02-10
Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-10 | Common Stock | M | 2271 | — | Acquired | 6379.2903 | Direct |
| 2023-02-10 | Common Stock | F | 685 | $286.30 | Disposed | 5694.2903 | Direct |
| 2023-02-10 | Common Stock | M | 340 | — | Acquired | 6034.2903 | Direct |
| 2023-02-10 | Common Stock | F | 537 | $286.30 | Disposed | 5497.2903 | Direct |
| 2023-02-10 | Common Stock | F | 165 | $286.30 | Disposed | 5332.2903 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-10 | Restricted Stock Unit | $0 | M | 2271 | Disposed | 2025-02-10 | Common Stock (2271) | Direct |
| 2023-02-10 | Restricted Stock Unit | $0 | M | 340 | Disposed | 2023-02-12 | Common Stock (340) | Direct |
| 2023-02-10 | Restricted Stock Unit | $0 | J | 416 | Disposed | 2023-02-12 | Common Stock (416) | Direct |
Footnotes
F1: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.
F2: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.
F3: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F4: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.